Onkologisches Zentrum Donauwörth

The medical center is at the forefront of hematology and oncology research, with a particular focus on polycythemia vera. This rare blood disorder is characterized by an overproduction of red blood cells, leading to increased blood viscosity and a heightened risk of thrombosis. The center's research aims to understand the mechanisms of hydroxyurea resistance in patients, utilizing advanced artificial intelligence techniques to identify predictive risk factors.

• Polycythemia Vera
• Hydroxyurea Resistance
• Artificial Intelligence in Medicine

By integrating machine learning into clinical practice, the center is pioneering personalized treatment strategies that enhance patient outcomes and improve quality of life for those affected by this condition.

Specializing in the treatment of hormone receptor positive HER2 negative breast cancer, the center is conducting innovative trials to explore the efficacy of combining Abemaciclib with endocrine therapy. This research is particularly focused on managing side effects through digital platforms, aiming to improve patient adherence and quality of life.

• Hormone Receptor Positive HER2 Negative Breast Cancer
• Abemaciclib and Endocrine Therapy
• Digital Side Effect Management

The center's work in this area is crucial for advancing treatment protocols and providing comprehensive care for patients with advanced or metastatic breast cancer, ensuring that therapeutic interventions are both effective and manageable.